Forum report: Issues in the design of trials of drugs for the treatment of invasive aspergillosis

John E. Bennett, John Powers, Ben De Pauw, William Dismukes, John N Galgiani, Michel Glauser, Raoul Herbrecht, Carol Kauffman, Jeannette Lee, Peter Pappas, John Rex, Paul Verweii, Claudio Viscoli, Thomas Walsh

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A recent trial of drugs for invasive aspergillosis was used as a background for discussing critical features in the design of antifungal trials. The study under discussion allowed stopping either drug without classifying the patient as having treatment failure, so the trial should be understood as a comparison of 2 treatment strategies, not just 2 drugs. Although the study was a noninferiority trial, the outcome permitted a claim of superiority. Use of the category of "probable" in addition to "proven" aspergillosis permitted inclusion of patients for whom the diagnosis was less certain but who were still early enough in the disease progression to respond to therapy. Different opinions still exist about some of the criteria for the diagnosis of "probable" aspergillosis. A blinded data review committee was helpful in evaluating efficacy in this unblinded trial but had limited value in assessing toxicity. An understanding of these features of design of antifungal drug trials is important in applying the results to clinical practice.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume36
Issue numberSUPPL. 3
DOIs
StatePublished - Apr 15 2003

Fingerprint

Aspergillosis
Drug Design
Pharmaceutical Preparations
Advisory Committees
Treatment Failure
Disease Progression
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Forum report : Issues in the design of trials of drugs for the treatment of invasive aspergillosis. / Bennett, John E.; Powers, John; De Pauw, Ben; Dismukes, William; Galgiani, John N; Glauser, Michel; Herbrecht, Raoul; Kauffman, Carol; Lee, Jeannette; Pappas, Peter; Rex, John; Verweii, Paul; Viscoli, Claudio; Walsh, Thomas.

In: Clinical Infectious Diseases, Vol. 36, No. SUPPL. 3, 15.04.2003.

Research output: Contribution to journalArticle

Bennett, JE, Powers, J, De Pauw, B, Dismukes, W, Galgiani, JN, Glauser, M, Herbrecht, R, Kauffman, C, Lee, J, Pappas, P, Rex, J, Verweii, P, Viscoli, C & Walsh, T 2003, 'Forum report: Issues in the design of trials of drugs for the treatment of invasive aspergillosis', Clinical Infectious Diseases, vol. 36, no. SUPPL. 3. https://doi.org/10.1086/367838
Bennett, John E. ; Powers, John ; De Pauw, Ben ; Dismukes, William ; Galgiani, John N ; Glauser, Michel ; Herbrecht, Raoul ; Kauffman, Carol ; Lee, Jeannette ; Pappas, Peter ; Rex, John ; Verweii, Paul ; Viscoli, Claudio ; Walsh, Thomas. / Forum report : Issues in the design of trials of drugs for the treatment of invasive aspergillosis. In: Clinical Infectious Diseases. 2003 ; Vol. 36, No. SUPPL. 3.
@article{21fe86e5a83c4e56ae7221865d61c632,
title = "Forum report: Issues in the design of trials of drugs for the treatment of invasive aspergillosis",
abstract = "A recent trial of drugs for invasive aspergillosis was used as a background for discussing critical features in the design of antifungal trials. The study under discussion allowed stopping either drug without classifying the patient as having treatment failure, so the trial should be understood as a comparison of 2 treatment strategies, not just 2 drugs. Although the study was a noninferiority trial, the outcome permitted a claim of superiority. Use of the category of {"}probable{"} in addition to {"}proven{"} aspergillosis permitted inclusion of patients for whom the diagnosis was less certain but who were still early enough in the disease progression to respond to therapy. Different opinions still exist about some of the criteria for the diagnosis of {"}probable{"} aspergillosis. A blinded data review committee was helpful in evaluating efficacy in this unblinded trial but had limited value in assessing toxicity. An understanding of these features of design of antifungal drug trials is important in applying the results to clinical practice.",
author = "Bennett, {John E.} and John Powers and {De Pauw}, Ben and William Dismukes and Galgiani, {John N} and Michel Glauser and Raoul Herbrecht and Carol Kauffman and Jeannette Lee and Peter Pappas and John Rex and Paul Verweii and Claudio Viscoli and Thomas Walsh",
year = "2003",
month = "4",
day = "15",
doi = "10.1086/367838",
language = "English (US)",
volume = "36",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Forum report

T2 - Issues in the design of trials of drugs for the treatment of invasive aspergillosis

AU - Bennett, John E.

AU - Powers, John

AU - De Pauw, Ben

AU - Dismukes, William

AU - Galgiani, John N

AU - Glauser, Michel

AU - Herbrecht, Raoul

AU - Kauffman, Carol

AU - Lee, Jeannette

AU - Pappas, Peter

AU - Rex, John

AU - Verweii, Paul

AU - Viscoli, Claudio

AU - Walsh, Thomas

PY - 2003/4/15

Y1 - 2003/4/15

N2 - A recent trial of drugs for invasive aspergillosis was used as a background for discussing critical features in the design of antifungal trials. The study under discussion allowed stopping either drug without classifying the patient as having treatment failure, so the trial should be understood as a comparison of 2 treatment strategies, not just 2 drugs. Although the study was a noninferiority trial, the outcome permitted a claim of superiority. Use of the category of "probable" in addition to "proven" aspergillosis permitted inclusion of patients for whom the diagnosis was less certain but who were still early enough in the disease progression to respond to therapy. Different opinions still exist about some of the criteria for the diagnosis of "probable" aspergillosis. A blinded data review committee was helpful in evaluating efficacy in this unblinded trial but had limited value in assessing toxicity. An understanding of these features of design of antifungal drug trials is important in applying the results to clinical practice.

AB - A recent trial of drugs for invasive aspergillosis was used as a background for discussing critical features in the design of antifungal trials. The study under discussion allowed stopping either drug without classifying the patient as having treatment failure, so the trial should be understood as a comparison of 2 treatment strategies, not just 2 drugs. Although the study was a noninferiority trial, the outcome permitted a claim of superiority. Use of the category of "probable" in addition to "proven" aspergillosis permitted inclusion of patients for whom the diagnosis was less certain but who were still early enough in the disease progression to respond to therapy. Different opinions still exist about some of the criteria for the diagnosis of "probable" aspergillosis. A blinded data review committee was helpful in evaluating efficacy in this unblinded trial but had limited value in assessing toxicity. An understanding of these features of design of antifungal drug trials is important in applying the results to clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=0037447121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037447121&partnerID=8YFLogxK

U2 - 10.1086/367838

DO - 10.1086/367838

M3 - Article

C2 - 12679894

AN - SCOPUS:0037447121

VL - 36

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 3

ER -